McGonegal didn't want to set expectations for the AppyScore NPV in the new phase III study, but I think it's very safe to assume that results from the new study have to improve on the 89% NPV recorded the last time around. Given the changes made to the new study, there is no reason why AppyScore shouldn't perform better.
What NPV score gets AppyScore approved by FDA? Again, McGonegal and Pusey don't have a specific number to throw out, saying that FDA has not set a specific efficacy hurdle for the test.
If I had to make an educated guess, AppyScore's new NPV must exceed 95%, and may even need to reach 98-99%, in order for 1) FDA to approve; and/or 2) for AppyScore to have any chance of being clinically relevant and therefore used by doctors in hospital emergency departments.
Right now, doctors using simple blood tests, patient exams and CT scans to diagnose appendicitis achieve NPV levels north of 95% and even as high as 99%. This is the real-world efficacy bar for AppyScore because if the test on its own can't beat the current standard of care, emergency rooms are only adding cost to the diagnosis of appendicitis without gaining any diagnostic value.AspenBio has, in the past, reasoned that one value of AppyScore could be the elimination of expensive CT scans from the diagnosis of appendicitis. True, in theory, except that AppyScore works by measuring a marker for inflammation. The test doesn't specifically screen for appendicitis. This means that most ER docs would likely still use a CT scan to make sure that it's the appendix and not some other nearby organ, which is in trouble. AspenBio shares, trading around $4.30, have almost doubled in value in the past two weeks, as the stock attracts the interest of retail investors and traders. Some of the information published about AspenBio on blog sites like Seeking Alpha is incorrect or omits key facts, so I'd be careful.
Sticking with Twitter, @bobbandera asks, "Seems Acura Pharmaceuticals (ACUR) has to take niacin out of all their drugs. How much of a delay is that? What's the procedure?"
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV